Cargando…

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC

SIMPLE SUMMARY: Intratumoral hypoxia is a negative prognostic factor in breast cancer progression and recurrence. By implementing a hypoxia fate-mapping system, we followed cells that experience intratumoral hypoxia in vivo and determined that these cells have an increased ability to metastasize com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godet, Inês, Mamo, Mahelet, Thurnheer, Andrea, Rosen, D. Marc, Gilkes, Daniele M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583122/ https://www.ncbi.nlm.nih.gov/pubmed/34771673 http://dx.doi.org/10.3390/cancers13215509

Ejemplares similares

Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis
por: Godet, Inês, et al.
Publicado: (2019)

A persistent invasive phenotype in post-hypoxic tumor cells is revealed by fate mapping and computational modeling
por: Rocha, Heber L., et al.
Publicado: (2021)

The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia
por: Bhatavdekar, Omkar, et al.
Publicado: (2022)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

A software tool for the quantification of metastatic colony growth dynamics and size distributions in vitro and in vivo
por: Bhoyar, Soumitra, et al.
Publicado: (2018)

The rise of viperin: the emerging role of viperin in cancer progression
por: Weinstein, Alyssa G., et al.
Publicado: (2022)

Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances
por: Godet, Inês, et al.
Publicado: (2022)

Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
por: Ferrari, Paola, et al.
Publicado: (2022)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
por: Wu, Ling, et al.
Publicado: (2019)

Encapsulation and adhesion of nanoparticles as a potential biomarker for TNBC cells metastatic propensity
por: Merkher, Yulia, et al.
Publicado: (2023)

Core promoter in TNBC is highly mutated with rich ethnic signature
por: Huang, Teng, et al.
Publicado: (2022)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
por: He, Jiabei, et al.
Publicado: (2019)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells
por: Joe, Natalie S., et al.
Publicado: (2023)

At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy
por: Sulaiman, Andrew, et al.
Publicado: (2022)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
por: Labrie, Marilyne, et al.
Publicado: (2021)

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
por: Joe, Natalie S., et al.
Publicado: (2022)

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021)

Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators
por: Wang, Yuze, et al.
Publicado: (2023)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
por: Petrosyan, Varduhi, et al.
Publicado: (2022)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC)
por: Zylla, Jessica L. S., et al.
Publicado: (2022)

Hypoxic Microenvironment and Metastatic Bone Disease
por: Hiraga, Toru
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pnt0aq7nr04j4eqrvmircmatv5